Table 1.

Cohort characteristics and outcomes: characteristics of the CKD (n=12) and other (general population and high cardiovascular risk; n=22) cohorts that could provide data for a 3-year antecedent period

VariableTotal SampleCKD CohortsOther Cohorts
N1,277,217249,9771,027,240
Median no. SCre (IQR)5 (4–5)7 (7–7)5 (4–5)
Slope <−5 ml/yr
 N, %111211
 Age (SD), yr58 (17)73 (11)54 (17)
 Women, %49960
 Black, %4151
Slope ≥−5 to ≤5 ml/yr
 N, %848085
 Age (SD), yr59 (17)76 (10)55 (16)
 Women, %48956
 Black, %290
Slope >5 ml/yr
 N, %574
 Age (SD), yr57 (19)73 (10)50 (17)
 Women, %481163
 Black, %3101
Mean (SD) follow-up,a yr3.2 (4.0)3 (1)3 (4)
ACM events102,47757,26945,208
CVM eventsb82313407891
  • Slope <−5 ml/yr is the declining eGFR group with an annualized eGFR slope of <−5 ml/min per 1.73 m2 per year. N, % is the proportion of the cohort belonging to a given slope category. Slope ≥−5 to ≤5 ml/yr is the stable eGFR group with an annualized GFR between ≥−5 and ≤5 ml/min per 1.73 m2 per year. Slope >5 ml/yr is the increasing eGFR group with an annualized eGFR slope of >5 ml/min per 1.73 m2 per year. SCre, serum creatinine measurements available during the antecedent period; CVM, cardiovascular mortality.

  • a Follow-up time refers to the at-risk period subsequent to the 3-year antecedent interval.

  • b Not all cohorts could provide data with respect to CVM (Supplemental Table 2).